Published in TB and Outbreaks Week, August 12th, 2003
"FR900098 represents an improved derivative of the new antimalarial drug fosmidomycin and acts through inhibition of the 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an essential enzyme of the mevalonate independent pathway of isoprenoid biosynthesis," scientists in Germany explained.
In a study conducted by R. Ortmann and colleagues at the University of Munich, FR900098 prodrugs "with increased activity after oral administration were obtained by chemical modification of the phosphonate moiety to yield acyloxyalkyl esters."
"The most successful...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.